Literature DB >> 10094895

Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma.

F V Price1, R M Amin, J Sumkin.   

Abstract

Three cases of serous carcinoma of the uterus with radiographically documented widespread metastases are presented. Following confirmation of histopathology, all were treated with a standard regimen of carboplatin and paclitaxel for eight courses with complete resolution of distant metastases on CT scan prior to postchemotherapy surgical exploration. Two patients had gross disease at laparotomy, and one had only microscopic tumor found in the uterine specimen. This experience offers rationale for treatment of patients with widely metastatic uterine serous carcinoma or other relative contraindications to surgery with primary carboplatin and paclitaxel. In addition, we believe this experience supports the hypothesis that this regimen may result in prolonged disease-free survival when employed as postsurgical adjuvant therapy. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094895     DOI: 10.1006/gyno.1998.5303

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer.

Authors:  N M de Lange; N P M Ezendam; J S Kwon; I Vandenput; D Mirchandani; F Amant; L J M van der Putten; J M A Pijnenborg
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

2.  Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?

Authors:  I Vandenput; B Van Calster; A Capoen; K Leunen; P Berteloot; P Neven; Ph Moerman; I Vergote; F Amant
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

3.  Clinicopathologic study in uterine cancer.

Authors:  I Vandenput
Journal:  Facts Views Vis Obgyn       Date:  2011
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.